Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.01276-24 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von He-Jun Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Institute of Clinical Immunology, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, COVID-19, Cyclosporine, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aimed to explore the effect of cyclosporine (CsA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in systemic lupus erythematosus (SLE) patients to provide a valuable reference for clinical treatment strategies in the context of the long-term risk of SARS-CoV-2 infection. SLE patients who visited the Rheumatology Outpatient Department of Fujian Medical University Union Hospital between 1 May and 31 October 2022 were included. Data on SARS-CoV-2 infection in patients between 1 November 2022 and 31 July 2023 were obtained by telephone follow-up. Patients were divided into two groups according to whether CsA was used during the observation period: the glucocorticoid or hydroxychloroquine group and the CsA group. To assess the robustness of the results, Data sets 1 and 2 were established to be analyzed independently. Multivariate logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for symptomatic coronavirus disease (COVID-19). A total of 184 patients were included, among whom 129 were definite symptomatic COVID-19 patients; 29 were presumptive symptomatic COVID-19 patients; and 4 had signs and symptoms of COVID-19, but tested negative for SARS-CoV-2 in a virological test. According to the multivariable-adjusted models, CsA was associated with lower odds of symptomatic COVID-19 ( P = 0.042, OR = 0.316, 95% CI: 0.104–0.959 in Data set 1 and P = 0.021, OR = 0.257, 95% CI: 0.081–0.812 in Data set 2). CsA is associated with lower odds of contracting symptomatic COVID-19. The use of CsA may be considered an appropriate therapeutic option for disease management in patients with rheumatic diseases who have severe disease activity and persistent SARS-CoV-2 infection. IMPORTANCE Our study indicated that cyclosporine may reduce the risk of symptomatic COVID-19 in systemic lupus erythematosus patients in spite of its immunosuppressive effects. This study provides a reference for clinical treatment strategies for AIIRD patients in the context of the long-term risk of SARS-CoV-2 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fujian Institute of Clinical Immunology, Fujian Medical University Union Hospital, Fuzhou, China.
- Department of Rheumatology, Fujian Medical University Union Hospital, Fuzhou, China.
- Department of Nephrology, Fujian Medical University Union Hospital, Fuzhou, China.
ORCID-Profile: He-Jun Li, Li-Xin Wei
Zitieren
APA
Li, H. J., Lin, S. H., Wang, Y. Q., Chen, L., Zheng, X. X., & Wei, L. X. (2024). Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01276-24
Vancouver
Li HJ, Lin SH, Wang YQ, Chen L, Zheng XX, Wei LX. Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study. Microbiology Spectrum. 2024. doi:10.1128/spectrum.01276-24
BibTeX
@article{Li2024,
author = {Li, He-Jun and Lin, Shu-Huan and Wang, Yan-Qing and Chen, Ling and Zheng, Xiang-Xiong and Wei, Li-Xin},
title = {Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.01276-24}
}
EUVIMED